Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Pivotal Study Recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Study Recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Biosciences Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma

Dec 4, 2014

Cellectar Biosciences Names Cameron Szakacs, Ph.D. Vice President of Clinical Development

Nov 25, 2014

Cellectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights

Nov 11, 2014

Cellectar Biosciences to Host Conference Call on November 11th to Discuss Third Quarter 2014 Results and Provide Quarterly Update on Development Progress

Nov 6, 2014

Cellectar Biosciences Announces Publication of Findings Demonstrating Efficacy of Its Phospholipid Ether Analog Platform in Detecting Colorectal Cancer

Oct 15, 2014

Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September

Sep 5, 2014

Cellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma

Sep 4, 2014

Cellectar Biosciences Reports Second Quarter 2014 Financial Results and Recent Highlights

Aug 20, 2014

Cellectar Biosciences Announces Closing of Public Offering and Partial Exercise of Underwriter's Over-Allotment Option

Aug 20, 2014

Cellectar Biosciences to Host Conference Call on August 20th to Discuss Second Quarter 2014 Results and Provide Quarterly Update on Development Progress

Aug 18, 2014
    • 1...
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    © 2022 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A